Tenet Healthcare
THC
$233.20
+17.17%
Tenet Healthcare is a Dallas-based healthcare services organization that operates acute and specialty hospitals, ambulatory surgery centers, and outpatient facilities across the United States, primarily in the South, along with a revenue cycle management segment called Conifer. As one of the largest for-profit hospital operators in the country, Tenet distinguishes itself through its integrated care delivery model and its Conifer business, which provides technology-enabled services to other healthcare providers. The current investor narrative centers on Tenet's ability to sustain margin expansion and earnings growth amid a challenging admissions mix, as highlighted by its recent Q1 2026 earnings beat and raised full-year profit outlook, even as revenue fell short of expectations due to unfavorable patient insurance mix.…
THC
Tenet Healthcare
$233.20
THC 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tenet Healthcare's 12-month outlook, with a consensus price target around $249.90 and implied upside of +7.2% versus the current price.
Average Target
$249.90
0 analysts
Implied Upside
+7.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$210 - $290
Analyst target range
Tenet is covered by 21 analysts, with a consensus recommendation of 'Strong Buy' (mean recommendation of 1.45 on a 1-5 scale). The average target price is $243.90, implying approximately +25.1% upside from the current price of $194.91. The distribution shows no sell ratings, with most analysts rating it Overweight or Buy, indicating strong bullish sentiment. The target price range spans from a low of $210.00 to a high of $288.00. The high target of $288.00 implies a potential upside of +47.8%, likely assuming margin expansion and growth acceleration, while the low target of $210.00 still suggests +7.7% upside, reflecting a more conservative view. Recent ratings from major firms (Wells Fargo, Barclays, TD Cowen, RBC Capital) have all maintained Overweight or Buy ratings, with no downgrades, reinforcing the positive consensus. The relatively tight spread between low and high targets ($78) suggests moderate conviction among analysts, though the unanimous bullish stance indicates confidence in Tenet's earnings trajectory and strategic initiatives.
Bulls vs Bears: THC Investment Factors
Tenet Healthcare presents a compelling value opportunity with strong earnings momentum, expanding margins, and a low valuation. The bull case is supported by a 25% upside to analyst targets, robust free cash flow, and unanimous analyst bullishness. However, bears point to decelerating revenue growth, high debt, and recent underperformance versus the market. The single most important tension is whether Tenet can sustain its margin expansion and earnings growth despite payer mix headwinds. If revenue growth reaccelerates or margins continue to improve, the stock could re-rate higher; if mix issues persist, the low valuation may be justified. Currently, the evidence slightly favors the bulls given the strong earnings beat and raised guidance, but the revenue deceleration warrants caution.
Bullish
- Strong earnings beat and raised guidance: Tenet reported Q1 2026 EPS of $8.09, well above estimates, and raised its full-year profit outlook. This demonstrates operational momentum and management confidence in sustaining margin expansion.
- Attractive valuation with 25% upside: The forward P/E of 10.96x and EV/EBITDA of 6.29x are low relative to history and peers. The average analyst target of $243.90 implies 25.1% upside from the current price of $194.91.
- Expanding margins and strong profitability: Net margin improved to 13.08% in Q1 2026 from 7.77% a year ago, driven by cost control and operating leverage. Operating margin rose to 16.43% from 15.72% in Q4 2025.
- Robust free cash flow generation: TTM free cash flow is $3.35 billion, providing ample liquidity for debt reduction, share buybacks, or strategic investments. Q1 2026 FCF alone was $1.46 billion.
Bearish
- Revenue growth deceleration and mix headwinds: Q1 2026 revenue grew only 2.78% YoY, down from 4.9% in Q4 2025 and 5.3% in Q3 2025. The miss was attributed to unfavorable patient insurance mix, which could pressure future revenue.
- High debt-to-equity ratio: Debt-to-equity stands at 3.12x, elevated even for the hospital industry. This leverage amplifies earnings volatility and interest expense ($205M per quarter) consumes cash flow.
- Stock underperforming market over 1 year: THC returned 11.29% over the past year versus the S&P 500's 18.35%, underperforming by 7.06%. The stock is also down 2.28% year-to-date while the market is up 9%.
- High beta and recent volatility: Beta of 1.266 makes THC 26.6% more volatile than the market. The stock has experienced a 34% max drawdown and currently sits 21% below its 52-week high of $247.21.
THC Technical Analysis
Tenet's stock is in a broad uptrend over the past year, with a 1-year price change of +11.29%, but it has experienced significant volatility. The current price of $194.91 sits at 38.7% of its 52-week range ($146.60 to $247.21), indicating it is closer to the low end after a sharp pullback from the highs. This positioning suggests the stock may be offering a value opportunity if the uptrend resumes, but it also reflects the recent selling pressure that has driven it well off its peak. Over the last three months, the stock has declined 0.88%, while the one-month change shows a strong rebound of +9.19%, indicating a short-term momentum shift. This divergence between the positive one-month and negative three-month trends suggests a potential short-term reversal or mean reversion attempt, though the longer-term trend remains cautious. The stock's beta of 1.266 implies it is 26.6% more volatile than the S&P 500, amplifying both upside and downside moves. Key support lies near the 52-week low of $146.60, while resistance is at the 52-week high of $247.21. A breakout above $247.21 would signal a resumption of the uptrend, while a breakdown below $146.60 could indicate further downside risk. The recent price action shows a bounce from the June lows around $161, suggesting short-term support near that level.
Beta
—
—
Max Drawdown
-34.1%
Largest decline past year
52-Week Range
$147-$247
Price range past year
Annual Return
+57.2%
Cumulative gain past year
| Period | THC Return | S&P 500 |
|---|---|---|
| 1m | +27.5% | +0.8% |
| 3m | +29.0% | +3.5% |
| 6m | +23.5% | +7.2% |
| 1y | +57.2% | +16.5% |
| ytd | +16.9% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
THC Fundamental Analysis
Tenet's revenue trajectory shows modest growth, with Q1 2026 revenue of $5.368 billion, up 2.78% year-over-year from $5.223 billion in Q1 2025. However, this growth rate has decelerated from the 4.9% YoY growth seen in Q4 2025 ($5.527 billion) and the 5.3% growth in Q3 2025 ($5.289 billion). The revenue miss in Q1 2026 was attributed to an unfavorable patient insurance mix, with hospital operations contributing $4.048 billion and ambulatory care $1.32 billion. The deceleration raises questions about volume trends and payer mix headwinds, though the raised full-year profit outlook suggests management sees improving operational efficiency. Tenet is highly profitable, with Q1 2026 net income of $702 million and a net margin of 13.08%, up from 6.71% in Q4 2025 and 7.77% in Q1 2025. Gross margin improved to 82.26% in Q1 2026 from 15.72% in Q4 2025 (note: gross margin varies due to revenue recognition; operating margin was 16.43% in Q1 2026 vs. 15.72% in Q4 2025). The expansion in net margin reflects strong cost control and operating leverage, with operating income of $882 million and EBITDA of $1.566 billion. Tenet's balance sheet shows a debt-to-equity ratio of 3.12, which is elevated but typical for the hospital industry. Free cash flow generation is robust, with TTM free cash flow of $3.349 billion and Q1 2026 free cash flow of $1.461 billion, providing ample liquidity. The current ratio of 1.76 indicates healthy short-term liquidity, and ROE of 33.34% reflects strong returns on equity, though leverage amplifies this metric.
Quarterly Revenue
$5.4B
2026-03
Revenue YoY Growth
+2.8%
YoY Comparison
Gross Margin
16.4%
Latest Quarter
Free Cash Flow
$3.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is THC Overvalued?
Given Tenet's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 12.73x, while the forward P/E is 10.96x, implying the market expects earnings growth over the next year. The gap between trailing and forward P/E suggests analysts anticipate continued earnings expansion, which aligns with the raised guidance. Compared to the industry average (Medical Care Facilities), Tenet's forward P/E of 10.96x appears reasonable, though specific industry averages are not provided. However, the EV/EBITDA of 6.29x is attractive relative to historical levels and peers, indicating potential undervaluation. Historically, Tenet's trailing P/E has ranged from as low as 1.21x (Q1 2024) to as high as 37.54x (Q2 2022). The current 12.73x is near the lower end of its historical range over the past few years, suggesting the stock is not overvalued relative to its own history. This low multiple could reflect market skepticism about the sustainability of earnings growth or concerns about the payer mix headwinds, but it also presents a potential value opportunity if the company can deliver on its raised guidance.
PE
12.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 1x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
6.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Tenet's high debt-to-equity ratio of 3.12x is a significant financial risk, as interest expense of $205 million per quarter consumes a portion of operating income. While free cash flow is strong at $3.35 billion TTM, any sustained downturn in earnings could strain debt servicing. Revenue growth deceleration to 2.78% YoY from 5%+ in prior quarters indicates potential volume or mix headwinds that could pressure margins if not managed. The net margin expansion to 13.08% is impressive but may be cyclical; a reversal could compress earnings quickly given the operating leverage.
Market & Competitive Risks: The stock's beta of 1.266 implies higher sensitivity to market downturns, and its year-to-date underperformance (-2.28% vs. S&P 500 +9%) suggests investor skepticism. Valuation compression risk exists if earnings growth disappoints, though the forward P/E of 10.96x already reflects modest expectations. Regulatory risks include potential changes to Medicaid or Medicare reimbursement, which could impact Tenet's payer mix. The recent news about unfavorable admissions mix highlights competitive pressures from other hospital systems and outpatient alternatives.
Worst-Case Scenario: A severe recession or adverse regulatory change could cause earnings to miss estimates, leading to analyst downgrades and multiple compression. The 52-week low of $146.60 represents a 24.8% downside from the current price of $194.91. In a worst-case scenario, the stock could fall to that level or below, resulting in a loss of approximately -25% to -35%. The historical max drawdown of -34.08% suggests such a decline is possible if fundamentals deteriorate significantly.